Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

Completed · Phase 1

Conditions studied: Lymphoma

In brief

Many cancer patients are prescribed drugs to which their cancer is already resistant - and thus suffer toxicity with no potential for benefit. Previous attempts to assess chemoresistance or sensitivity in vitro have failed. This is a feasibility study in human patients with newly diagnosed or recurrent lymphoma to determine how human cancerous lymph nodes in situ respond to standard of care therapeutics precisely microinjected with the CIVO(tm) microdosing system.

Key facts

Study ID
NCT01831505
Run by
Presage Biosciences
People needed
4
Starts
2012-11-01
Expected to finish
2013-07-01
Last updated by the study team
2017-02-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.